That’s the big idea behind Zymosense, “The Nanoassay Company,” a startup that’s spinning off technology developed in the lab ...
In 2025, landmark obesity drug deals, China’s biotech surge, and AI’s deeper integration into pharma operations drove a year of transformation and renewed momentum for life sciences. From high-stakes ...
Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund XBI, a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 SPX by 9 ...
Commentary: Biotechnology lets scientists engineer natural ingredients into products, often more sustainably than if they were farmed. Here's what to know. Deenie is a CNET Perspectives contributor ...
In September 2024, Akeso, a little-known Chinese biopharmaceutical company, announced that clinical trials had shown that its new drug could halt the progression of a type of lung cancer for nearly a ...
Something unusual is happening to biotech stocks: They’re going up. A drug-pricing deal between Pfizer and the White House and a spate of deals have sent the SPDR S&P Biotech exchange-traded fund up 9 ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
‘Disheartening? Yes. Surprising? No.’ Report on the future of biotech in Mass. gives a grim outlook.
The industry group MassBio released its annual temperature check on the state’s biotech industry Tuesday, and the results are grim. Both public and private funding have plummeted as federal policy ...
The first microchip was invented in Texas in the 1950s, but many of today’s most advanced chips are made in Taiwan and South Korea. Last week, the U.S. government purchased a 10% stake in the ...
George is a professor of genetics at Harvard Medical School and professor of health sciences and technology at Harvard and MIT. He is a prolific researcher studying genetic sequencing, genome editing, ...
Mr. Dreyer is an American editor and writer who lives in Shanghai. Just outside Shanghai, in the city of Wuxi, China is building its future of medicine — a booming biotechnology hub of factories and ...
As biotech companies struggle, laying off staff and cutting drug research, a well-funded firm in Southern California watches closely for the right time to strike. This year, it’s struck again and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback